Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (301-310 of 471) with videos related to

Pageof 48
Sort By:
Crohn'S & Colitis 360|June 18, 2021
Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, MinnesotaZeinab Bakhshi, Siddhant Yadav, Bradley R Salonen, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 21, 2021
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's DiseaseWilliam J Sandborn, James D Lewis, Julian Panes, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based studyNicole M Gentile, Sahil Khanna, Edward V Loftus, et al.
The American Journal of Gastroenterology|September 13, 2008
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's diseaseKelvin T Thia, William J Sandborn, James D Lewis, et al.
Gastrointestinal Endoscopy|December 24, 2019
Indomethacin for post-ERCP pancreatitis: Prophylaxis at what cost?Andrew C Storm, Barham K Abu Dayyeh, Bret T Petersen, et al.
Gastroenterology|June 18, 2021
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)Laurent Peyrin-Biroulet, Edward V Loftus, Jean-Frédéric Colombel, et al.
Inflammatory Bowel Diseases|November 23, 2006
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitisJeanne Tung, Edward V Loftus, Deborah K Freese, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2022
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trialsLaurent Peyrin-Biroulet, Subrata Ghosh, Scott D Lee, et al.
Pageof 48

Showing results (301-310 of 471) with videos related to

Sort By:
Pageof 48
Crohn'S & Colitis 360|June 18, 2021
Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, MinnesotaZeinab Bakhshi, Siddhant Yadav, Bradley R Salonen, et al.
European Journal of Gastroenterology & Hepatology|February 28, 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studiesGeert D'Haens, Filip Baert, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 21, 2021
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's DiseaseWilliam J Sandborn, James D Lewis, Julian Panes, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based studyNicole M Gentile, Sahil Khanna, Edward V Loftus, et al.
The American Journal of Gastroenterology|September 13, 2008
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's diseaseKelvin T Thia, William J Sandborn, James D Lewis, et al.
Gastrointestinal Endoscopy|December 24, 2019
Indomethacin for post-ERCP pancreatitis: Prophylaxis at what cost?Andrew C Storm, Barham K Abu Dayyeh, Bret T Petersen, et al.
Gastroenterology|June 18, 2021
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)Laurent Peyrin-Biroulet, Edward V Loftus, Jean-Frédéric Colombel, et al.
Inflammatory Bowel Diseases|November 23, 2006
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitisJeanne Tung, Edward V Loftus, Deborah K Freese, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2022
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trialsLaurent Peyrin-Biroulet, Subrata Ghosh, Scott D Lee, et al.
Pageof 48